Arcutis Biotherapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Arcutis Biotherapeutics sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
Arcutis Biotherapeutics: 25 sponsored US clinical trials, 2 recruiting.
Arcutis Biotherapeutics sponsors 25 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 22 completed. 9 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Seborrheic Dermatitis, with 1 trials.
Top-decile sponsor footprint
Arcutis Biotherapeutics ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
22 of 23 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
25 total, page 1 of 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
NCT07453602
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
NCT07340216
Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
NCT06998056
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
NCT05028582
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
NCT04973228
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
NCT04845620
Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
NCT04811131
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
NCT04746911
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
NCT04804605
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
NCT04773600
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
NCT04773587
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)
NCT04655313
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
NCT04445987
Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
NCT04378569
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis
NCT04279119
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
NCT04286607
Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
NCT04128007
Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema
NCT04156191
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
NCT04211363
Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
NCT04211389
Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
NCT04091646
Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
NCT03916081
Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis
NCT03764475
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
NCT03638258
Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis
NCT03392168
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 10 |
| Phase 3 | 9 |
Therapeutic Areas
What is open in the Arcutis Biotherapeutics pipeline
2 recruiting of 25 indexed (8% open); 22 completed (88%).
Phase mix: 9 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Seborrheic Dermatitis (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Arcutis Biotherapeutics: open-pipeline peers nationwide
Peers matched on 25 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Arcutis Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 trials (± recruiting share)
- Arcus Biosciences · 25 trials · 12% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
- Fisher and Paykel Healthcare · 25 trials · 4% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Medtronic Endovascular · 8% recruiting · 25 trials
- Novartis Pharmaceuticals · 8% recruiting · 1,375 trials
- Penumbra · 8% recruiting · 25 trials
- SK Life Science · 8% recruiting · 25 trials
Related
What to do with this Arcutis Biotherapeutics page
25 registered trials is a research-attention snapshot, not an endorsement of Arcutis Biotherapeutics or any single study.
- 2 of Arcutis Biotherapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Seborrheic Dermatitis is the condition Arcutis Biotherapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Seborrheic Dermatitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Arcutis Biotherapeutics pipeline card: 25 registered trials from official public datasets.Report a data error.